BiotechTube

Vamorolone + Eplerenone + Fludrocortisone

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacodynamic

Conditions

Pharmacodynamic

Trial Timeline

Jun 5, 2024 → Jul 6, 2024

NCT ID
NCT06649409

About Vamorolone + Eplerenone + Fludrocortisone

Vamorolone + Eplerenone + Fludrocortisone is a phase 1 stage product being developed by Santhera Pharmaceuticals for Pharmacodynamic. The current trial status is completed. This product is registered under clinical trial identifier NCT06649409. Target conditions include Pharmacodynamic.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06649409Phase 1Completed

Competing Products

10 competing products in Pharmacodynamic

See all competitors
ProductCompanyStageHype Score
GP40141 + NplateGEROPHARMPhase 1
25
Darexaban + Acetyl Salicylic Acid (ASA)Astellas PharmaPhase 1
33
darexaban + darexaban (double dose) + Acetyl Salicylic Acid + clopidogrelAstellas PharmaPhase 1
33
darexaban + NaproxenAstellas PharmaPhase 1
33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tabletsAstraZenecaPhase 1
33
D961H + OmeprazoleAstraZenecaPhase 1
33
Dienogest (81150037) + Dienogest (81150231) + Dienogest (SH T00660A) + Dienogest (81150746)BayerPhase 1
30
5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)IdorsiaPhase 1
28
VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large)VaxartPhase 1
25

Other Products from Santhera Pharmaceuticals

vamorolone 40 mg/mL oral suspensionApproved
77
IdebenoneApproved
77
Placebo + IdebenonePhase 3
69
idebenonePhase 3
69
idebenone + PlaceboPhase 3
69